Columbia University Medical Center and University of Iowa scientists have used a new gene-editing technology called CRISPR, to repair a genetic mutation responsible for retinitis pigmentosa (RP), an inherited condition that causes the retina to degrade…
Q&A With Detroit’s New Director of Public Health
(MedPage Today) — Abdul El Sayed, MD, is optimistic about reinventing a collapsed system
What Would Single-Payer Mean for Doctors?
(MedPage Today) — Experts outline the pros and cons
Uncategorized
Katena Products acquires Sensor Medical Technology
Katena Products announced its acquisition of Sensor Medical Technology, in a press release.Sensor Medical Technology specializes in developing and manufacturing high quality single-use and reusable diagnostic and therapeutic lenses used by optometrists…
Uncategorized
Novartis appoints Mike Ball to lead Alcon, announces business changes for 2016
Novartis has appointed Mike Ball as division head and CEO of Alcon, effective Feb. 1. He will succeed Jeff George.“I want to welcome Mike Ball as division head and CEO of Alcon. His expertise in ophthalmology, as well as medical devices, will be instrumental in accelerating innovation and growth at Alcon,” Joseph Jimenez, CEO of Novartis, said in a press release.
Current Therapeutic Developments in Atrophic AMD
More effective therapies are on the horizon for atrophic AMD. Find out what’s new. The British Journal of Ophthalmology